Slideshows Images Quizzes

Northera

Last reviewed on RxList: 2/24/2017
Northera Side Effects Center

Last reviewed on RxList 02/24/2017

Northera (droxidopa) is a synthetic amino acid precursor of norepinephrine used for the treatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic orthostatic hypotension (NOH) caused by primary autonomic failure [Parkinson's disease (PD), multiple system atrophy and pure autonomic failure], dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Common side effects of Northera include:

The recommended starting dose of Northera is 100 mg, taken orally three times daily: upon arising in the morning, at midday, and in the late afternoon at least 3 hours prior to bedtime (to reduce the potential for hypertension during sleep). Northera may interact with other drugs that increase blood pressure (e.g., norepinephrine, ephedrine, midodrine, and triptans), or Parkinson's medications. Tell your doctor all medications and supplements you use. During pregnancy, Northera should be used only if prescribed. This drug may pass into breast milk and could have undesirable effects on a nursing infant. Breastfeeding is not recommended while using Northera.

Our Northera (droxidopa) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Northera Professional Information

SIDE EFFECTS

The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety evaluation of NORTHERA is based on two placebo-controlled studies 1 to 2 weeks in duration (Studies 301 and 302), one 8-week placebo-controlled study (Study 306), and two long-term, open-label extension studies (Studies 303 and 304). In the placebo-controlled studies, a total of 485 patients with Parkinson's disease, multiple system atrophy, pure autonomic failure, dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy were randomized and treated, 245 with NORTHERA and 240 with placebo [see Clinical Studies].

Placebo-Controlled Experience

The most commonly observed adverse reactions (those occurring at an incidence of greater than 5% in the NORTHERA group and with at least a 3% greater incidence in the NORTHERA group than in the placebo group) in NORTHERA-treated patients during the three placebo-controlled trials were headache, dizziness, nausea, and hypertension. The most common adverse reactions leading to discontinuation from NORTHERA were hypertension or increased blood pressure and nausea.

Table 1: Most Common Adverse Reactions Occurring More Frequently in the NORTHERA Group

  Study 301 and Study 302 (1 to 2 Weeks Randomized Treatment) Study 306 (8 to 10 Weeks Randomized Treatment)
Placebo
(N=132) n (%)
NORTHERA
(N=131) n (%)
Placebo
(N=108) n (%)
NORTHERA
(N=114) n (%)
Headache 4 (3.0) 8 (6.1) 8 (7.4) 15 (13.2)
Dizziness 2 (1.5) 5 (3.8) 5 (4.6) 11 (9.6)
Nausea 2 (1.5) 2 (1.5) 5 (4.6) 10 (8.8)
Hypertension 0 2 (1.5) 1 (0.9) 8 (7.0)

Note: n=number of patients. Adverse reactions that were reported in greater than 5% of patients in the NORTHERA group and with at least a 3% greater incidence in the NORTHERA group than in the placebo group were from Study 306.

Long-Term, Open-Label Trials With NORTHERA

In the long-term, open-label extension studies, a total of 422 patients, mean age 65 years, were treated with NORTHERA for a mean total exposure of approximately one year. The commonly reported adverse events were falls (24%), urinary tract infections (15%), headache (13%), syncope (13%), and dizziness (10%).

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of NORTHERA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Cardiac Disorders: Chest pain

Eye Disorders: Blurred vision

Gastrointestinal Disorders: Pancreatitis, abdominal pain, vomiting, diarrhea

General Disorders and Administration Site Conditions: Fatigue

Nervous System Disorders: Cerebrovascular accident

Psychiatric Disorders: Psychosis, hallucination, delirium, agitation, memory disorder

Read the entire FDA prescribing information for Northera (Droxidopa Capsules)

Related Resources for Northera

Related Drugs

© Northera Patient Information is supplied by Cerner Multum, Inc. and Northera Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors